Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic pharmaceutical company Mylan (MYL) has earned a respected four-star ranking.
With that in mind, let's take a closer look at Mylan and see what CAPS investors are saying about the stock right now.
Mylan facts
|
Headquarters (founded) |
Canonsburg, Pa. (1961) |
|
Market Cap |
$11.4 billion |
|
Industry |
Pharmaceuticals |
|
Trailing-12-Month Revenue |
$6.8 billion |
|
Management |
CEO Heather Bresch |
|
Return on Equity (average, past 3 years) |
14.7% |
|
Cash/Debt |
$409.5 million / $5.7 billion |
|
Competitors |
Abbott Labs |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 94% of the 569 members who have rated Mylan believe the stock will outperform the S&P 500 going forward.
Earlier this year, one of those Fools, brenoboyle, succinctly summed up the bull case for our community:
Mylan has seen and should continue to see rapidly expanding revenues due to the patent cliff and expanding prescription drug coverage. Add a robust share repurchase program and [less than] 11x forward earnings is a pittance to pay for a stock that has trounced the S&P over the past 5 years.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
